Suggested Remit: To appraise the clinical and cost effectiveness of luspatercept within its marketing authorisation for treating anaemia caused by myelodysplastic syndromes.
 
Status Proposed
Process STA 2018
ID number 1550

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
28 May 2019 - 25 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance